In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...

The Philadelphia-based biotech, founded and run by Jim Wilson, M.D., Ph.D., will receive up to $100 million from the Oswaldo ...

Several months after forging a fresh path forward for its troubled Friedreich ataxia (FA) drug vatiquinone, PTC Therapeutics ...

The patient was in his 60s, an African American man with emphysema. | State attorneys general and U.S. senators have pressed ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

Black Diamond Therapeutics has deprioritized one of its two clinical-stage lung cancer contenders, jettisoned two executives ...

Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. | Mestag ...

Medtronic has been notifying users of its MiniMed insulin pumps to be aware of potentially shortened battery lives, and to ...

The FDA has given a green light to an at-home test that checks for both COVID-19 and the flu—a first for the agency, outside ...